Treat to target, remission and low disease activity in SLE

Eric F. Morand, Marta Mosca

Research output: Contribution to journalReview ArticleResearchpeer-review

6 Citations (Scopus)

Abstract

Despite improvements in survival, outcomes of contemporary treatment of systemic lupus erythematosus (SLE) are unacceptable. Unlike in many diseases, treat-to-target (T2T) approaches have not been adopted in SLE, owing to a lack of validated targets to treat towards. Therefore, it is a key goal to validate target state definitions such as low disease activity and remission, and test their implementation in clinical practice and clinical trials. In this article, we review recent advances in T2T approaches in SLE, and emerging evidence-based consensus on definitions of remission and low disease activity that are needed to underpin such approaches. We conclude that, while more work is needed, much has been achieved and at least for low disease activity the lupus low disease activity state definition appears to have utility and validity for the study of SLE. Application to routine clinical care awaits validation of improved outcomes from T2T studies based on these targets.

Original languageEnglish
Pages (from-to)342-350
Number of pages9
JournalBest Practice and Research: Clinical Rheumatology
Volume31
Issue number3
DOIs
Publication statusPublished - 1 Jun 2017

Keywords

  • Low disease activity
  • Remission
  • Systemic lupus erythematosus
  • Treat to target

Cite this

@article{7d443d0076b64cdbbe6e99ac3355bd34,
title = "Treat to target, remission and low disease activity in SLE",
abstract = "Despite improvements in survival, outcomes of contemporary treatment of systemic lupus erythematosus (SLE) are unacceptable. Unlike in many diseases, treat-to-target (T2T) approaches have not been adopted in SLE, owing to a lack of validated targets to treat towards. Therefore, it is a key goal to validate target state definitions such as low disease activity and remission, and test their implementation in clinical practice and clinical trials. In this article, we review recent advances in T2T approaches in SLE, and emerging evidence-based consensus on definitions of remission and low disease activity that are needed to underpin such approaches. We conclude that, while more work is needed, much has been achieved and at least for low disease activity the lupus low disease activity state definition appears to have utility and validity for the study of SLE. Application to routine clinical care awaits validation of improved outcomes from T2T studies based on these targets.",
keywords = "Low disease activity, Remission, Systemic lupus erythematosus, Treat to target",
author = "Morand, {Eric F.} and Marta Mosca",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.berh.2017.09.009",
language = "English",
volume = "31",
pages = "342--350",
journal = "Best Practice and Research: Clinical Rheumatology",
issn = "1521-6942",
publisher = "Elsevier",
number = "3",

}

Treat to target, remission and low disease activity in SLE. / Morand, Eric F.; Mosca, Marta.

In: Best Practice and Research: Clinical Rheumatology, Vol. 31, No. 3, 01.06.2017, p. 342-350.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Treat to target, remission and low disease activity in SLE

AU - Morand, Eric F.

AU - Mosca, Marta

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Despite improvements in survival, outcomes of contemporary treatment of systemic lupus erythematosus (SLE) are unacceptable. Unlike in many diseases, treat-to-target (T2T) approaches have not been adopted in SLE, owing to a lack of validated targets to treat towards. Therefore, it is a key goal to validate target state definitions such as low disease activity and remission, and test their implementation in clinical practice and clinical trials. In this article, we review recent advances in T2T approaches in SLE, and emerging evidence-based consensus on definitions of remission and low disease activity that are needed to underpin such approaches. We conclude that, while more work is needed, much has been achieved and at least for low disease activity the lupus low disease activity state definition appears to have utility and validity for the study of SLE. Application to routine clinical care awaits validation of improved outcomes from T2T studies based on these targets.

AB - Despite improvements in survival, outcomes of contemporary treatment of systemic lupus erythematosus (SLE) are unacceptable. Unlike in many diseases, treat-to-target (T2T) approaches have not been adopted in SLE, owing to a lack of validated targets to treat towards. Therefore, it is a key goal to validate target state definitions such as low disease activity and remission, and test their implementation in clinical practice and clinical trials. In this article, we review recent advances in T2T approaches in SLE, and emerging evidence-based consensus on definitions of remission and low disease activity that are needed to underpin such approaches. We conclude that, while more work is needed, much has been achieved and at least for low disease activity the lupus low disease activity state definition appears to have utility and validity for the study of SLE. Application to routine clinical care awaits validation of improved outcomes from T2T studies based on these targets.

KW - Low disease activity

KW - Remission

KW - Systemic lupus erythematosus

KW - Treat to target

UR - http://www.scopus.com/inward/record.url?scp=85031331022&partnerID=8YFLogxK

U2 - 10.1016/j.berh.2017.09.009

DO - 10.1016/j.berh.2017.09.009

M3 - Review Article

VL - 31

SP - 342

EP - 350

JO - Best Practice and Research: Clinical Rheumatology

JF - Best Practice and Research: Clinical Rheumatology

SN - 1521-6942

IS - 3

ER -